

# 18<sup>th</sup> Annual Discovery on TARGET

September 16-18, 2020

VIRTUAL



EVENT AT-A-GLANCE

WEDNESDAY September 16	Target Identification and Validation – Part 1	RNA as a Drug Target	PROTACs and Targeted Protein Degradation – Part 1	Lead and Candidate Selection for Therapeutic Proteins	Antibodies Against Membrane Protein Targets – Part 1	Small G Proteins	Immunology and Oncology: Emerging Drug Targets and Therapeutics	Targeting NASH	Disease Modeling	CNS, Gene and Cell Therapy	
	Short Course		Insights into PROTACs and Targeted Protein Degradation								
THURSDAY September 17	Short Course		<i>In vitro and in vivo</i> Modeling for Cancer Research								
	Target Identification and Validation – Part 1	RNA as a Drug Target	PROTACs and Targeted Protein Degradation – Part 1	Lead and Candidate Selection for Therapeutic Proteins	Antibodies Against Membrane Protein Targets – Part 1	Small G Proteins	Immunology and Oncology: Emerging Drug Targets and Therapeutics	Targeting NASH	Disease Modeling	CNS, Gene and Cell Therapy	
	Plenary Keynote Program										
	Target Identification and Validation – Part 2	Lead Generation Strategies	PROTACs and Targeted Protein Degradation – Part 2	Modality Selection for Next-Gen Biotherapeutics	Antibodies Against Membrane Protein Targets – Part 2	Kinase Inhibitor Discovery	GPCR-Based Drug Discovery	Targeting Fibrosis	Preclinical Strategies, Models and Tools in Oncology	Clinical and Translational Biomarkers	
FRIDAY September 18	Target Identification and Validation – Part 2	Lead Generation Strategies	PROTACs and Targeted Protein Degradation – Part 2	Modality Selection for Next-Gen Biotherapeutics	Antibodies Against Membrane Protein Targets – Part 2	Kinase Inhibitor Discovery	GPCR-Based Drug Discovery	Targeting Fibrosis	Preclinical Strategies, Models and Tools in Oncology	Clinical and Translational Biomarkers	
	Short Course		Artificial Intelligence and Machine Learning in Drug Discovery and Development								



#BostonDOT20

DiscoveryonTARGET.com

